AU2021211874A1 - Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure - Google Patents
Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure Download PDFInfo
- Publication number
- AU2021211874A1 AU2021211874A1 AU2021211874A AU2021211874A AU2021211874A1 AU 2021211874 A1 AU2021211874 A1 AU 2021211874A1 AU 2021211874 A AU2021211874 A AU 2021211874A AU 2021211874 A AU2021211874 A AU 2021211874A AU 2021211874 A1 AU2021211874 A1 AU 2021211874A1
- Authority
- AU
- Australia
- Prior art keywords
- mydgf
- heart failure
- variant
- hypertrophy
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20153008 | 2020-01-21 | ||
| EP20153008.6 | 2020-01-21 | ||
| PCT/EP2021/051079 WO2021148411A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021211874A1 true AU2021211874A1 (en) | 2022-08-25 |
Family
ID=69187588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021211874A Pending AU2021211874A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230059560A1 (https=) |
| EP (1) | EP4093750A1 (https=) |
| JP (1) | JP7777532B2 (https=) |
| KR (1) | KR20220131262A (https=) |
| CN (1) | CN115698048A (https=) |
| AU (1) | AU2021211874A1 (https=) |
| BR (1) | BR112022014272A2 (https=) |
| CA (2) | CA3164500A1 (https=) |
| MX (1) | MX2022008727A (https=) |
| PH (1) | PH12022551792A1 (https=) |
| TW (1) | TW202142254A (https=) |
| WO (1) | WO2021148411A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022066729A1 (en) * | 2020-09-22 | 2022-03-31 | Wisconsin Alumni Research Foundation | Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor |
| US20250325704A1 (en) | 2020-12-23 | 2025-10-23 | Boehringer Ingelheim International Gmbh | Viral capsid proteins with specificity to heart tissue cells |
| CN115820829B (zh) * | 2022-03-22 | 2026-04-17 | 中国人民解放军军事科学院军事医学研究院 | Mydgf在防治记忆损伤及其相关疾病中的应用 |
| JP2025518285A (ja) | 2022-06-03 | 2025-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄由来増殖因子の組換え発現 |
| JP2025530232A (ja) | 2022-09-08 | 2025-09-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心原性ショックの処置に用いる骨髄由来成長因子 |
| EP4480490A1 (en) * | 2023-06-23 | 2024-12-25 | Medizinische Hochschule Hannover | Brick1 for use in treating myocardial diseases |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| TW202539726A (zh) | 2023-12-06 | 2025-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 包含骨髓衍生性生長因子之新穎調配物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| AU717542B2 (en) | 1996-06-11 | 2000-03-30 | Merck & Co., Inc. | Synthetic hepatitis C genes |
| WO1998011217A2 (en) * | 1996-09-13 | 1998-03-19 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS |
| JP2001506484A (ja) | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| CA2503390A1 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004069173A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US20080004232A1 (en) | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| DK2945642T3 (da) * | 2013-01-17 | 2024-05-27 | Medizinische Hochschule Hannover | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme |
| JP7405772B2 (ja) * | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| WO2020176732A1 (en) * | 2019-02-27 | 2020-09-03 | Icahn School Of Medicine At Mount Sinai | TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY |
-
2021
- 2021-01-19 US US17/759,056 patent/US20230059560A1/en active Pending
- 2021-01-19 EP EP21701283.0A patent/EP4093750A1/en active Pending
- 2021-01-19 CA CA3164500A patent/CA3164500A1/en active Pending
- 2021-01-19 TW TW110102010A patent/TW202142254A/zh unknown
- 2021-01-19 BR BR112022014272A patent/BR112022014272A2/pt unknown
- 2021-01-19 CN CN202180022864.1A patent/CN115698048A/zh active Pending
- 2021-01-19 JP JP2022544144A patent/JP7777532B2/ja active Active
- 2021-01-19 AU AU2021211874A patent/AU2021211874A1/en active Pending
- 2021-01-19 WO PCT/EP2021/051079 patent/WO2021148411A1/en not_active Ceased
- 2021-01-19 MX MX2022008727A patent/MX2022008727A/es unknown
- 2021-01-19 PH PH1/2022/551792A patent/PH12022551792A1/en unknown
- 2021-01-19 KR KR1020227027546A patent/KR20220131262A/ko active Pending
- 2021-01-19 CA CA3223879A patent/CA3223879A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022551792A1 (en) | 2023-09-18 |
| EP4093750A1 (en) | 2022-11-30 |
| MX2022008727A (es) | 2022-10-07 |
| CA3164500A1 (en) | 2021-07-29 |
| WO2021148411A1 (en) | 2021-07-29 |
| JP7777532B2 (ja) | 2025-11-28 |
| KR20220131262A (ko) | 2022-09-27 |
| TW202142254A (zh) | 2021-11-16 |
| JP2023511358A (ja) | 2023-03-17 |
| CN115698048A (zh) | 2023-02-03 |
| US20230059560A1 (en) | 2023-02-23 |
| CA3223879A1 (en) | 2021-07-29 |
| BR112022014272A2 (pt) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7777532B2 (ja) | 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子 | |
| Hunley et al. | Update on endothelins–biology and clinical implications | |
| EP2945642A2 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| US11820981B2 (en) | Modulation of TJP1 expression to regulate regeneration of heart cells | |
| EP3658157A1 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| JP2009019032A (ja) | 血管形成及び心臓血管新生の促進又は阻害 | |
| JPWO2004022753A1 (ja) | アクチン関連新規細胞骨格タンパク質ｌａｃｓ | |
| Xiang et al. | LITAF acts as a novel regulator for pathological cardiac hypertrophy | |
| US11944671B2 (en) | Hippo pathway deficiency reverses systolic heart failure post-infarction | |
| EP4480490A1 (en) | Brick1 for use in treating myocardial diseases | |
| WO2024052564A1 (en) | Myeloid-derived growth factor for use in treating cardiogenic shock | |
| EA053022B1 (ru) | Фактор роста миелоидного происхождения для применения при лечении или профилактике фиброза, гипертрофии или сердечной недостаточности | |
| TW201200151A (en) | Methods and compositions related to reduced MET phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells | |
| JP2026506629A (ja) | 心臓機能を改善するための変異体ｙａｐの使用 | |
| CN116925205A (zh) | 激活Hippo信号通路的多肽及其用途 | |
| HK40088501A (zh) | 用於治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子 | |
| Yang et al. | Cardiac fibroblasts-specific USP7 drives post-infarction cardiac fibrosis by deubiquitinating Krüppel-like factor 7 to promote myofibroblast activation | |
| Coleman | The pharmacology and physiology of orphan G protein-coupled receptor, GPR37L1 | |
| HK40029335A (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| HK40042415A (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| JP2012012330A (ja) | 癌転移抑制剤及び医薬組成物 | |
| EP2874629A1 (en) | Inhibitors of nkx2.5 for vascular remodelling |